Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Marta Sandini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2932-5218; OpenAlex author ID A5026244101. Sources: OpenAlex.

Their work

Papers
16 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
69
Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: 3 papers · 2019: none · 2020: 6 papers · 2021: none · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: 1 paper

Papers 16

  1. Collagen XVII Promotes Pancreatic Ductal Adenocarcinoma Tumor Growth through Regulation of PIK3R5. Co-author DOI 10.1158/2767-9764.crc-24-0392↗
  2. Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant treatment. Co-author DOI 10.1016/j.ejso.2022.12.006↗
  3. Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective,… Co-author DOI 10.3389/fnut.2023.1065294↗
  4. Independent effect of fat-to-muscle mass ratio at bioimpedance analysis on long-term survival in patients receiving surgery for pancreatic cancer. Co-author DOI 10.3389/fnut.2023.1118616↗
  5. Corrigendum: Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: a r… Co-author DOI 10.3389/fnut.2023.1212436↗
  6. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… First author DOI 10.1097/sla.0000000000004143↗
  7. Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy-Reply. First author DOI 10.1001/jamasurg.2019.5091↗
  8. Diabetes mellitus is associated with unfavorable pathologic features, increased postoperative mortality, and worse long-term survival in resected pancreatic ca… First author DOI 10.1016/j.pan.2019.10.007↗
  9. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003123↗
  10. Microscopic size measurements in post-neoadjuvant therapy resections of pancreatic ductal adenocarcinoma (PDAC) predict patient outcomes. Co-author DOI 10.1111/his.14067↗
  11. Main Pancreatic Duct to Parenchymal Thickness Ratio at Preoperative Imaging is Associated with Overall Survival in Upfront Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08040-0↗
  12. Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08515-5↗
  13. Association Between Changes in Body Composition and Neoadjuvant Treatment for Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.0979↗
  14. Neoadjuvant Therapy Versus Upfront Resection for Pancreatic Cancer: The Actual Spectrum and Clinical Burden of Postoperative Complications. Co-author DOI 10.1245/s10434-017-6281-9↗
  15. Intraoperative Dexamethasone Decreases Infectious Complications After Pancreaticoduodenectomy and is Associated with Long-Term Survival in Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6827-5↗
  16. The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis. First author DOI 10.1016/j.ejso.2016.02.003↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Carlos F. Fernandez-del Castillo · 7 shared papers, 2018–2025 · strength 0.90
  2. Keith D. Lillemoe · 8 shared papers, 2018–2025 · strength 0.88
  3. Salvatore Paiella · 8 shared papers, 2016–2023 · strength 0.86
  4. Thomas P. Hank · 6 shared papers, 2020–2025 · strength 0.83
  5. Roberto Salvia · 7 shared papers, 2016–2023 · strength 0.80
  6. Luca Vittorio Gianotti · 7 shared papers, 2016–2023 · strength 0.78
  7. Andrew Louis Warshaw · 6 shared papers, 2018–2025 · strength 0.72
  8. Claudio Bassi · 7 shared papers, 2016–2023 · strength 0.71
  9. Motaz Qadan · 6 shared papers, 2018–2022 · strength 0.62
  10. Giuseppe Malleo · 5 shared papers, 2018–2023 · strength 0.58
  11. Alessandro Zerbi · 4 shared papers, 2023 · strength 0.57
  12. Cristina Rosa Ferrone · 5 shared papers, 2018–2020 · strength 0.47
  13. Mari A. Mino-Kenudson · 3 shared papers, 2020–2025 · strength 0.43
  14. Giovanni Luigi Capretti · 3 shared papers, 2023 · strength 0.42
  15. Kim C. Honselmann · 3 shared papers, 2018–2025 · strength 0.36
  16. Erica Secchettin · 3 shared papers, 2020–2023 · strength 0.35
  17. Ilaria Trestini · 3 shared papers, 2020–2023 · strength 0.35
  18. Michèle Milella · 3 shared papers, 2020–2023 · strength 0.35
  19. Laura Maggino · 3 shared papers, 2018–2023 · strength 0.34
  20. Jon Michael Harrison · 2 shared papers, 2022–2025 · strength 0.33
  21. David Tsai Ting · 2 shared papers, 2020–2025 · strength 0.30
  22. Louisa Bolm · 2 shared papers, 2020–2025 · strength 0.30
  23. Matteo De Pastena · 2 shared papers, 2023 · strength 0.26
  24. Darío Gregori · 2 shared papers, 2023 · strength 0.26
  25. Riccardo Casadei · 2 shared papers, 2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.